CL2014001862A1 - Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. - Google Patents
Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.Info
- Publication number
- CL2014001862A1 CL2014001862A1 CL2014001862A CL2014001862A CL2014001862A1 CL 2014001862 A1 CL2014001862 A1 CL 2014001862A1 CL 2014001862 A CL2014001862 A CL 2014001862A CL 2014001862 A CL2014001862 A CL 2014001862A CL 2014001862 A1 CL2014001862 A1 CL 2014001862A1
- Authority
- CL
- Chile
- Prior art keywords
- moropholinyl
- mogat
- hypertriglyceridemia
- inhibitors
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000006575 hypertriglyceridemia Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382037 | 2012-01-31 | ||
| US201261617093P | 2012-03-29 | 2012-03-29 | |
| EP12382433 | 2012-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001862A1 true CL2014001862A1 (es) | 2014-11-14 |
Family
ID=48905712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001862A CL2014001862A1 (es) | 2012-01-31 | 2014-07-15 | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8993568B2 (https=) |
| EP (1) | EP2809661B1 (https=) |
| JP (1) | JP5852269B2 (https=) |
| KR (1) | KR20140107641A (https=) |
| CN (1) | CN104080777B (https=) |
| AP (1) | AP2014007793A0 (https=) |
| AU (1) | AU2013215549B2 (https=) |
| BR (1) | BR112014018712A8 (https=) |
| CA (1) | CA2859992A1 (https=) |
| CL (1) | CL2014001862A1 (https=) |
| CO (1) | CO7020914A2 (https=) |
| CR (1) | CR20140325A (https=) |
| DO (1) | DOP2014000177A (https=) |
| EA (1) | EA024182B1 (https=) |
| ES (1) | ES2571577T3 (https=) |
| GT (1) | GT201400169A (https=) |
| IL (1) | IL233542A0 (https=) |
| MX (1) | MX2014008604A (https=) |
| PE (1) | PE20141789A1 (https=) |
| PH (1) | PH12014501712B1 (https=) |
| SG (1) | SG11201404508XA (https=) |
| WO (1) | WO2013116065A1 (https=) |
| ZA (1) | ZA201405227B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9073856B2 (en) | 2012-01-23 | 2015-07-07 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors |
| AR089771A1 (es) | 2012-01-31 | 2014-09-17 | Lilly Co Eli | Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 |
| JP5852269B2 (ja) | 2012-01-31 | 2016-02-03 | イーライ リリー アンド カンパニー | Ｍｏｇａｔ−２阻害剤として有用な新規モルホリニル誘導体 |
| MX2015005739A (es) | 2012-11-06 | 2015-09-16 | Lilly Co Eli | Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2. |
| US10335401B2 (en) | 2015-12-21 | 2019-07-02 | Shionogi & Co., Ltd. | Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity |
| TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| CA3126334A1 (en) | 2019-01-11 | 2020-07-16 | Shionogi & Co., Ltd. | Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| GB9702194D0 (en) | 1997-02-04 | 1997-03-26 | Lilly Co Eli | Sulphonide derivatives |
| WO2000006539A1 (en) | 1998-07-31 | 2000-02-10 | Eli Lilly And Company | Alkenyl sulphonamide derivatives |
| AU5235699A (en) | 1998-07-31 | 2000-02-21 | Eli Lilly And Company | Sulfonamide derivatives |
| GB0408777D0 (en) | 2004-04-20 | 2004-05-26 | Glaxo Group Ltd | Compounds |
| EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| EP1655283A1 (en) | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
| US8232282B2 (en) | 2006-09-28 | 2012-07-31 | Dainippon Sumitomo Pharma Co., Ltd. | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same |
| TW200831092A (en) * | 2006-12-21 | 2008-08-01 | Astrazeneca Ab | Therapeutic agents |
| US20090203695A1 (en) * | 2007-12-05 | 2009-08-13 | Biovitrum Ab | Compounds IV |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2272841A1 (en) | 2008-03-28 | 2011-01-12 | Banyu Pharmaceutical Co., Ltd. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
| JP2011522006A (ja) | 2008-06-04 | 2011-07-28 | アストラゼネカ アクチボラグ | 新規化合物ｖ |
| US20110275647A1 (en) | 2009-02-23 | 2011-11-10 | Msd K.K. | Pyrimidin-4-(3h)-one derivatives |
| JP2014051434A (ja) | 2010-12-28 | 2014-03-20 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体 |
| US9073856B2 (en) | 2012-01-23 | 2015-07-07 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors |
| JP5852269B2 (ja) | 2012-01-31 | 2016-02-03 | イーライ リリー アンド カンパニー | Ｍｏｇａｔ−２阻害剤として有用な新規モルホリニル誘導体 |
| AR089771A1 (es) | 2012-01-31 | 2014-09-17 | Lilly Co Eli | Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 |
| MX2015005739A (es) | 2012-11-06 | 2015-09-16 | Lilly Co Eli | Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2. |
-
2013
- 2013-01-24 JP JP2014554806A patent/JP5852269B2/ja not_active Expired - Fee Related
- 2013-01-24 CN CN201380007113.8A patent/CN104080777B/zh not_active Expired - Fee Related
- 2013-01-24 AP AP2014007793A patent/AP2014007793A0/xx unknown
- 2013-01-24 EP EP13702564.9A patent/EP2809661B1/en active Active
- 2013-01-24 SG SG11201404508XA patent/SG11201404508XA/en unknown
- 2013-01-24 CA CA2859992A patent/CA2859992A1/en not_active Abandoned
- 2013-01-24 KR KR1020147021129A patent/KR20140107641A/ko not_active Abandoned
- 2013-01-24 PE PE2014001194A patent/PE20141789A1/es not_active Application Discontinuation
- 2013-01-24 BR BR112014018712A patent/BR112014018712A8/pt not_active IP Right Cessation
- 2013-01-24 ES ES13702564T patent/ES2571577T3/es active Active
- 2013-01-24 WO PCT/US2013/022828 patent/WO2013116065A1/en not_active Ceased
- 2013-01-24 MX MX2014008604A patent/MX2014008604A/es unknown
- 2013-01-24 AU AU2013215549A patent/AU2013215549B2/en not_active Ceased
- 2013-01-24 US US14/372,833 patent/US8993568B2/en not_active Expired - Fee Related
- 2013-01-24 EA EA201491227A patent/EA024182B1/ru not_active IP Right Cessation
-
2014
- 2014-07-07 IL IL233542A patent/IL233542A0/en unknown
- 2014-07-08 CR CR20140325A patent/CR20140325A/es unknown
- 2014-07-15 CL CL2014001862A patent/CL2014001862A1/es unknown
- 2014-07-16 ZA ZA2014/05227A patent/ZA201405227B/en unknown
- 2014-07-24 CO CO14161421A patent/CO7020914A2/es unknown
- 2014-07-29 GT GT201400169A patent/GT201400169A/es unknown
- 2014-07-30 PH PH12014501712A patent/PH12014501712B1/en unknown
- 2014-07-30 DO DO2014000177A patent/DOP2014000177A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104080777B (zh) | 2015-12-09 |
| EA024182B1 (ru) | 2016-08-31 |
| CR20140325A (es) | 2014-08-25 |
| JP2015504917A (ja) | 2015-02-16 |
| ZA201405227B (en) | 2016-05-25 |
| EP2809661A1 (en) | 2014-12-10 |
| HK1199024A1 (zh) | 2015-06-19 |
| AP2014007793A0 (en) | 2014-07-31 |
| US8993568B2 (en) | 2015-03-31 |
| PH12014501712A1 (en) | 2014-10-13 |
| AU2013215549A1 (en) | 2014-07-17 |
| CA2859992A1 (en) | 2013-08-08 |
| PE20141789A1 (es) | 2014-11-19 |
| MX2014008604A (es) | 2014-08-22 |
| PH12014501712B1 (en) | 2014-10-13 |
| EP2809661B1 (en) | 2016-04-06 |
| IL233542A0 (en) | 2014-08-31 |
| GT201400169A (es) | 2015-08-27 |
| BR112014018712A2 (https=) | 2017-06-20 |
| AU2013215549B2 (en) | 2015-09-03 |
| DOP2014000177A (es) | 2014-08-31 |
| WO2013116065A1 (en) | 2013-08-08 |
| JP5852269B2 (ja) | 2016-02-03 |
| CO7020914A2 (es) | 2014-08-11 |
| ES2571577T3 (es) | 2016-05-26 |
| KR20140107641A (ko) | 2014-09-04 |
| US20150005305A1 (en) | 2015-01-01 |
| BR112014018712A8 (pt) | 2017-07-11 |
| EA201491227A1 (ru) | 2015-01-30 |
| CN104080777A (zh) | 2014-10-01 |
| SG11201404508XA (en) | 2014-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2015000177A1 (es) | Composición para el tratamiento de la hiperlipidemia que comprende un derivado de oxintomodulina | |
| CL2015003280A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
| CL2014003136A1 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos. | |
| CL2015001733A1 (es) | Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer. | |
| LT2916860T (lt) | Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą | |
| CL2014001065A1 (es) | Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer. | |
| CR20140259A (es) | Compuestos novedosos de benzopirano, composiciones y usos de los mismos | |
| LT2984166T (lt) | Kompozicijos, skirtos mpsi gydymui | |
| CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
| CL2013003019A1 (es) | Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| CL2014003462A1 (es) | Uso de compuestos aminotriazolopiridinas sustituidos, en el tratamiento de afecciones inflamatorias, autoinmunitarias, proliferativas, alergias, rechazo de trasplantes, entre otras; composicion farmaceutica que los comprende; combinacion farmaceutica. | |
| EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
| CL2014002257A1 (es) | Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer. | |
| AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| DK3043778T3 (da) | Farmaceutiske sammensætninger, der indeholder refametinib | |
| LT3386991T (lt) | Policikliniai junginiai, kaip brutono tirozinkinazės inhibitoriai | |
| CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
| BR112015002824A2 (pt) | composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação. |